WO1997011721A1 - Procede pour identifier des composes therapeutiquement actifs - Google Patents
Procede pour identifier des composes therapeutiquement actifs Download PDFInfo
- Publication number
- WO1997011721A1 WO1997011721A1 PCT/SE1996/001183 SE9601183W WO9711721A1 WO 1997011721 A1 WO1997011721 A1 WO 1997011721A1 SE 9601183 W SE9601183 W SE 9601183W WO 9711721 A1 WO9711721 A1 WO 9711721A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pylori
- animal
- mice
- strain
- mouse
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 150000001875 compounds Chemical class 0.000 title claims abstract description 14
- 241000699670 Mus sp. Species 0.000 claims abstract description 72
- 208000015181 infectious disease Diseases 0.000 claims abstract description 49
- 241001465754 Metazoa Species 0.000 claims abstract description 39
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 33
- 241000282414 Homo sapiens Species 0.000 claims abstract description 18
- 238000011081 inoculation Methods 0.000 claims abstract description 17
- 241000283984 Rodentia Species 0.000 claims abstract description 15
- 238000012360 testing method Methods 0.000 claims abstract description 13
- 208000007882 Gastritis Diseases 0.000 claims abstract description 12
- 241000282412 Homo Species 0.000 claims abstract description 8
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 8
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 6
- 206010019375 Helicobacter infections Diseases 0.000 claims abstract description 5
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 4
- 210000002784 stomach Anatomy 0.000 claims description 19
- 241000124008 Mammalia Species 0.000 claims description 11
- 241000700159 Rattus Species 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 5
- 239000000523 sample Substances 0.000 claims description 5
- 230000009858 acid secretion Effects 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 229960000381 omeprazole Drugs 0.000 claims description 3
- 238000011808 rodent model Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 239000000090 biomarker Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940126409 proton pump inhibitor Drugs 0.000 claims 2
- 239000000612 proton pump inhibitor Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- -1 drugs and agents Chemical class 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000006207 intravenous dosage form Substances 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000006203 subcutaneous dosage form Substances 0.000 claims 1
- 238000010171 animal model Methods 0.000 abstract description 22
- 238000011161 development Methods 0.000 abstract description 7
- 229960005486 vaccine Drugs 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 4
- 229940125575 vaccine candidate Drugs 0.000 abstract description 4
- 238000002405 diagnostic procedure Methods 0.000 abstract description 3
- 241000894006 Bacteria Species 0.000 description 15
- 238000001574 biopsy Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 238000012809 post-inoculation Methods 0.000 description 7
- 230000001332 colony forming effect Effects 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 102000009016 Cholera Toxin Human genes 0.000 description 4
- 108010049048 Cholera Toxin Proteins 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 208000034309 Bacterial disease carrier Diseases 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 108010046334 Urease Proteins 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 210000004203 pyloric antrum Anatomy 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000012895 Gastric disease Diseases 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010017865 Gastritis erosive Diseases 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 208000028861 Helicobacter pylori infectious disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- OXNGKCPRVRBHPO-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O OXNGKCPRVRBHPO-XLMUYGLTSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 238000006395 oxidase reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
Definitions
- the present invention relates to a method for identification of compounds and vaccine candidates suitable for the therapeutic treatment of gastric disorders associated with Helicobacter infections. More particularly, the present invention relates to providing in vivo animal models useful in the screening and evaluation of prophylactic and therapeutic agents and vaccines for the treatment of gastritis, ulcer and other gastroduodenal diseases associated with Helicobacter pylon infections. The animal models provided by the present invention may also be useful in the development of diagnostic tests for such infections.
- H pylori The relationship between gastroduodenal disorders and infections with Helicobacter pylori (H pylori ) is well established today.
- Helicobacter pylori was previously named Campylobacter pylori or Campylobacter pyloridis or just Campylobacter like organisms.
- the names H pylori , C pylori and C pyloridis are used interchangable.
- the above-mentioned relationship has been discussed by, for instance, Marchall et al, Microbios Lett. 25: 83 - 88 (1984). Marchall isolated C pyloridis from human gastric mucosa. Goodwin et al, J.Clin. Pathol. 39: 353 - 365 (1986) also suggested that gastroduodenal ulceration is associated with C pyloridis.
- H pylori invades and colonizes the stomach, its mode of action, such as persistence and role in gastroduodenal ulceration are important for the studies concerning the development of new therapies for the treatment of H pylori infections and related gastroduodenal diseases. At present there is no single compound therapy or treatment regimen which consistently provides eradication of said infections. Experimental work for studying H pylori related infections cannot be successfully investigated on human patients, due to ethical regulations.
- Immunologically compentent rodents and especially some specific mouse strains, have now surprisingly been found to be capable of developing infections by H pylori .
- Fresh isolates obtained directly from human gastric mucosa are used to establish H pylori infection.
- the new animal models can also be used in the development of vaccines against such infections and related diseases. Further, the animal models may be useful in the development of diagnostic tests for such infections.
- the H pylori infection is detectable 8 - 10 days following inoculation.
- Fresh isolates obtained from H pylori strains are used for inoculation. These fresh isolates are isolated from human patients. The isolates have not been passaged in animals, but they have in most instances been stored in a -70°C to minirnize laboratory passage (in vitro passage).
- New Zealand Black inbred mouse strain is New Zealand Black inbred mouse strain, shortly named NZB mice.
- Other inbred mouse strains which can be used in the method according to the present invention are the mouse strains named KK and DBA-1.
- KK and DBA-1 mouse strains have been previously used in biomedical research concerned with autoimmune diseases, see for instance, the International Index of Laboratory Animals, 6th edition, Michael F.W. Festing (1993).
- Another rodent of interest for the present invention is an immunocompetent rat, such as Sprague-Dawley rats.
- the latter have been inoculated by bacteria reisolated from colonized mice, i.e. human isolates which have been passaged in mice.
- H pylori In order to be useful as a screening model for H pylori, animals must be susceptible to infection with H pylori and especially with fresh isolates of H pylori obtained from humans. Moreover, to establish adequate H pylori infection in the animals, the immunological status of the specific animal and the virulence of the infecting organism are important factors.
- NZB mice are developed by Dr. Bielschowsky in 1970 as black-coated inbred mouse strains (Bieleshowsky et al. Cancer Res. 30: 834 ). It has to be noted that the NZB mice used according to the present invention are not genetically or immunologically transformed. The mice can be either of male or female sex. NZB mice are not previously known to have been infected by H pylori. They are hithereto used as standard animal for studies of the ethiology and pathogenisis of autoimmune diseases and therapeutic effect of immunosuppressive agents.
- the new animal models can be used in a method for identifying therapeutically active compounds for treatment of H pylori infections in mammals and man, wherein the method includes the following steps
- Immunologically compentent rodent of interest are inbred mouse strains, such as New Zealand Black mouse, DBA-1 mouse and KK mouse as well as rats.
- the invention discloses a method for identifying biological probes clinically useful for detecting H pylori infections in mammals including humans.
- Such methods include for instance a biological indicator suspected of interacting selectively with H pylori or a substance interacting with a product released by the bacteria and identifying a selective positive interaction with such a released product for detecting H pylori infections in mammals.
- Figure 1 shows the number of H pylori colony forming units, i e bacteria, recovered from the stomach biopsies of NZB mice 1 to 10 weeks post inoculation.
- Figures 2 (a) and 2 (b) show the number of H pylori colony forming units, i e bacteria, recovered from the stomach biopsies of DBA-1 mice and KK mice respectively 1 to 5 weeks post inoculation.
- Figure 3 shows that H pylori colonization occurs around the crypts in the lamina propia of infected mouse stomach.
- Figure 4 shows that H pylori- specific antibodies bind to the H pylori colonizing the stomach, i e are present on the thin-sectioned samples of infected NZB mouse stomach, confirr ing the colonizing bacteria of H pylori, by fluorescence staining.
- Figure 5 shows in 5(a) a scanning electromicroscope (SEM) picture showing the presence of H pylori in the mucus blanket of the gastric epithelium.
- 5(b) shows H pylori cultivated in vitro and sedimented on a filter paper, used for comparison.
- Figure 6 shows the results from therapeutic immunisation in H pylori infected mice. Mice infected were NZB and DBA, respectively.
- mice of the inbred mouse strain NZB were used.
- the mice were of male or female sex.
- the mice were bred and maintained in specific pathogen-free conditions and were examined to ensure the absence of specific bacteria and common murine diseases. They were housed in conventional Mak III cages and kept in room temperature, 50 - 60% relative humidity and fresh air exchange in accordance with Swedish regulations on Laboratory Animal Care.
- the mice were fed with autoclaved commercial rodent diet and sterile drinking water ad libitum. In some instances the animals did not receive any food, i e only water, 24 hours before the inoculation of bacteria.
- mice Prior to inoculation with bacteria some of the mice were given antibiotics per os for 3 days. Such optional antibiotic treatment of the animals was made to eliminate interference of normal flora competing with the experimentally inoculated H pylori. Doses of antibiotics were 40mg/ml Ampicillin; 200 mg/ml Nalidixan; 40 mg/ml metronidazole; 160 mg/ml Vancomycin; 200 mg/ml Trimethoprin and each mouse received 0.3 ml of antibiotics twice a day up to 4 hours before adrninistration of bacteria. Some of the mice were not pretreated with antibiotics before the inoculation with H pylori.
- mice were pretreated with an inhibitor of intragastric acid secretion to increase the gastric pH in the animal before inoculation with H pylori.
- an inhibitor of intragastric acid secretion used in the experimental studies was omeprazole.
- mice from the inbred mouse strains DBA-1 and KK were also tested as animals for the in vivo model useful in the screening method according to the present invention. These mice from the mouse strains DBA-1 and KK were treated in the same way as the NZB mice. Also immunocompetent Sprague-Dawley rats were inoculated with H pylori.
- mice 9 male sex.
- the mice were inoculated per os with 0.2 ml of H pylori (6 x 10 bact/ml) in peptone water.
- H pylori 6 x 10 bact/ml
- peptone water As a control mice of the different species were inoculated with 0.2 ml peptone water.
- Bacterial colonization and infection were followed up to 5 weeks post inoculation for DBA-1 and KK mice, and up to 10 weeks post inoculation for NZB mice.
- H pylori strain A-9 and another strain AH 69 isolated from the stomach of a human patient with duodenal ulcer were used for inoculation of NZB mice, female sex.
- the strain AH 69 was also used for infection of NZB and DBA mice.
- the therapeutic effect was evaluated in oral immunization experiment four weeks post infection.
- mice were inoculated by bacteria reisolated from mice colonized with H pylori.
- the colonized mice had been inoculated with the H pylori strain AH 69 isolated from a human patient with duodenal ulcer.
- the rats were pretreated with omeprazole to increase the intragastric pH before inoculation with the bacteria.
- H pylori strain A-9 was recovered from the pyloric- antrum region of the stomach of 8 out of 9 mice, two weeks post inoculation. Four weeks later H pylori could be recovered from all mice inoculated. An average number of 1 000 bacteria/ 25 mm 2 stomach biopsies could be recovered.
- the biopsies were homogenized and were analysed for urease, catalase and oxidase production. All analysed biopsy homogenates showed a rapid positive urease, catalase and oxidase reaction. None of the biopsy homogenates from the control group showed positive reactions.
- strain A-9 produced large proportions of spreading colonies and all were motile.
- the motility was rapid and directional.
- Bacteria isolated from the stomach of inoculated mice were assayed for DNA dependent discriminary ribotyping and quantitative PCR tests.
- the DNA pattern as well as PCR confirmed that those bacteria isolated from the stomach of the infected mice were identical to the inoculum H pylori strain A-9 or strain A-l 8 originally isolated from human gastritis patients.
- H pylori adhesion to epithelial tissue is partly mediated via Lewis b (Le ) receptors.
- mice were infected with mouse passaged fresh isolates H pylon, strain AH69. Oral immunizations were started four weeks post infection and from the first immunization day (day 1), mice were subsequently immunized on day 15, 25 and 35. One group mice was dosed with vehicle including Cholera toxin (CT) 10 ⁇ g/ mouse/ dose, and one group with the combination of CT + Membrane proteins (Mp). There were ten mice in each group.
- CT Cholera toxin
- Mp Membrane proteins
- CFU Colony forming units
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
L'invention concerne un procédé pour identifier des composés et vaccins thérapeutiques actifs contre les infections à Helicobacter pylori, faisant intervenir un modèle animal in vivo. Selon ce procédé, on inocule une souche de H. pylori associée à une gastrite chez les humains à un animal rongeur immunologiquement compétent, sélectionné dans un des groupes de souris NZB, DBA, KK ou à un rat. Ensuite, on administre à l'animal infecté un composé test ou un vaccin candidat afin de déterminer l'efficacité dudit composé ou vaccin contre l'infection en question. L'invention concerne également l'utilisation dudit modèle animal dans le développement de tests diagnostiques pour de telles infections ainsi qu'une souris Nouvelle-Zélande Black (NZB) infectée par des souches de Helicobacter pylori humaines.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU71024/96A AU7102496A (en) | 1995-09-25 | 1996-09-23 | Method to identify therapeutically active compounds |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9503309A SE9503309D0 (sv) | 1995-09-25 | 1995-09-25 | Method to identify therapeutically active compounds |
| SE9503309-8 | 1995-09-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997011721A1 true WO1997011721A1 (fr) | 1997-04-03 |
Family
ID=20399582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/SE1996/001183 WO1997011721A1 (fr) | 1995-09-25 | 1996-09-23 | Procede pour identifier des composes therapeutiquement actifs |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU7102496A (fr) |
| SE (1) | SE9503309D0 (fr) |
| WO (1) | WO1997011721A1 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999035907A3 (fr) * | 1998-01-16 | 1999-09-23 | Chiron Spa | Modele |
| RU2186394C2 (ru) * | 2000-01-31 | 2002-07-27 | Белая Юлия Александровна | Способ получения диагностикума для выявления антигенов helicobacter pylori в реакции коагглютинации |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996009757A1 (fr) * | 1994-09-28 | 1996-04-04 | Biocine Spa | Modele souris d'infection a helicobacter pylori |
| WO1996018291A1 (fr) * | 1994-12-13 | 1996-06-20 | Yoshitomi Pharmaceutical Industries, Ltd. | Gerbille de mongolie colonisee par helicobacter pylori, procede pour realiser cette colonisation, milieu pour la separation de helicobacter pylori et procede d'evaluation preliminaire de substances actives contre helicobacter pylori |
-
1995
- 1995-09-25 SE SE9503309A patent/SE9503309D0/xx unknown
-
1996
- 1996-09-23 WO PCT/SE1996/001183 patent/WO1997011721A1/fr active Application Filing
- 1996-09-23 AU AU71024/96A patent/AU7102496A/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996009757A1 (fr) * | 1994-09-28 | 1996-04-04 | Biocine Spa | Modele souris d'infection a helicobacter pylori |
| WO1996018291A1 (fr) * | 1994-12-13 | 1996-06-20 | Yoshitomi Pharmaceutical Industries, Ltd. | Gerbille de mongolie colonisee par helicobacter pylori, procede pour realiser cette colonisation, milieu pour la separation de helicobacter pylori et procede d'evaluation preliminaire de substances actives contre helicobacter pylori |
Non-Patent Citations (2)
| Title |
|---|
| EUROPEAN H PYLORI STUDY GROUP, A.A. McCOLM et al., "Screening of Anti-Helicobacter Therapies in Mice Colonised with H. Pylori"; VIIIth International Workshop on Gastro-Duodenal Pathology an Helicobacter Pylori 7-9th July 1995 Edinburgh, Scotland, page A92. * |
| THE AMERICAN JOURNAL OF GASTROENTEROLOGY, VOlume 89, No. 2, 1994, MIKIO KARITA et al., "Establishment of a Small Animal Model for Human Helicobacter Pylori Infection Using Germ-Free Mouse", page 208. * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999035907A3 (fr) * | 1998-01-16 | 1999-09-23 | Chiron Spa | Modele |
| RU2186394C2 (ru) * | 2000-01-31 | 2002-07-27 | Белая Юлия Александровна | Способ получения диагностикума для выявления антигенов helicobacter pylori в реакции коагглютинации |
Also Published As
| Publication number | Publication date |
|---|---|
| SE9503309D0 (sv) | 1995-09-25 |
| AU7102496A (en) | 1997-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Giguère et al. | Clinical manifestations, diagnosis, treatment, and prevention of Rhodococcus equi infections in foals | |
| Neiger et al. | Helicobacter infection in dogs and cats: facts and fiction | |
| Fox et al. | Helicobacter pylori-induced gastritis in the domestic cat | |
| Fox et al. | Persistent hepatitis and enterocolitis in germfree mice infected with Helicobacter hepaticus | |
| JP4666772B2 (ja) | Ｉｂｄ関連微生物抗原、およびｉｂｄ関連微生物抗原を使用する方法 | |
| DE69529219T2 (de) | Helicobacter proteine und impstoffe | |
| JP6201982B2 (ja) | 糖尿病誘起細菌 | |
| US5262156A (en) | Antigenic compositions and their use for the detection of Helicobacter pylori | |
| Yokota et al. | Colonization of Helicobacter pylori in the gastric mucosa of Mongolian gerbils | |
| Andrutis et al. | Infection of the ferret stomach by isogenic flagellar mutant strains of Helicobacter mustelae | |
| EP1666058B1 (fr) | Méthode pour la détection de l'infection par Pseudomonas aeruginosa | |
| US9068007B2 (en) | Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease | |
| JP4467973B2 (ja) | 非機能性ｐ２ｘ７リセプターに対応する抗体、癌及びその他の症状の診断及び治療 | |
| CZ96697A3 (en) | Isolated nucleic acid encoding heliobacter pylori antigen, vector in which it is comprised, purified antigenic preparation being encoded thereby, detection method of the heliobacter pylori strain presence, method of determining pre-diathesis for peptic ulcer, method of determining pre-diathesis for stomach carcinoma, heliobacter pylori mutant and heliobacter pylori strain | |
| Mégraud | 5 Diagnosis of Helicobacter pylori | |
| Hampson et al. | A Review-Intestinal spirochaetal infections of pigs: An overview with an Australian perspective | |
| Suzuki et al. | SS1 Helicobacter pylori disrupts the paracellular barrier of the gastric mucosa and leads to neutrophilic gastritis in mice | |
| Slee et al. | Enteritis in cattle due to Yersinia pseudotuberculosis infection | |
| Fox et al. | Helicobacter mustelae infection in ferrets: pathogenesis, epizootiology, diagnosis, and treatment | |
| WO1997011721A1 (fr) | Procede pour identifier des composes therapeutiquement actifs | |
| US6884412B1 (en) | Dectection of and methods and composition for prevention and/or treatment of papillomatous digital dermatitis | |
| Whary et al. | Promotion of ulcerative duodenitis in young ferrets by oral immunization with Helicobacter mustelae and muramyl dipeptide | |
| US7749512B2 (en) | Porcine Helicobacter infection | |
| US9176135B2 (en) | Method for predicting and preventing cardiovascular disease | |
| Udainiya et al. | Infectious Abortive Diseases: Brucellosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENP | Entry into the national phase |
Ref country code: US Ref document number: 1996 727593 Date of ref document: 19961112 Kind code of ref document: A Format of ref document f/p: F |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |